June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
The Burden of Glaucoma on Canadian Patients: Gaps in Understanding the Disease and its Treatments
Author Affiliations & Notes
  • Doug Earle
    Fighting Blindness Canada, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships   Doug Earle, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2670. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Doug Earle; The Burden of Glaucoma on Canadian Patients: Gaps in Understanding the Disease and its Treatments. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2670.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Affecting over 400,000 Canadians, glaucoma is a disease of the optic nerve and one of the leading causes of blindness in North America. This study seeks to better understand the daily struggles of living with glaucoma, and to offer the resulting analysis as a framework for guiding decisions related to new treatments in Canada.

Methods : Designed to collect data on the physical, psychological, financial, and other burdens associated with glaucoma, an online, IRB-approved survey was posted to Fighting Blindness Canada’s website on July 20, 2018, where it gathered responses over the course of several months. Data was analyzed for themes, patterns, and keywords.

Results : 244 Canadian respondents self-confirmed living with glaucoma. Patients rated the “severity of vision loss resulting from your glaucoma” on a scale from 1 to 10: most indicated 1 for “no vision loss” (24%), followed by ratings of 2 (17%), 3 (14%), 4 (12%), and 8 (7%). Patients were also asked about how serious they consider their disease to be, how often they think about it, what kinds of barriers they face, what kind of activities they find difficult, what types of treatments they take, and which treatments they are aware of.

Conclusions : A review of both qualitative and quantitative data showed that, especially in the context of an overall paucity of literature on the subject, there are significant gaps in our collective understanding of glaucoma: (1) gaps in our general understanding of the burdens associated with the disease; (2) gaps in the patient’s understanding of the treatment landscape; and (3) gaps in how patients understand the specific details of their own disease and diagnosis. A discussion of these gaps is the primary focus of this presentation.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×